Malaysia
Search
Sign In
Change Password
Points
Sign Out
Multidisciplinary
Top Medical News
Among postmenopausal women, diabetes status is correlated with an increased risk of subsequent glaucoma, a recent Korea study has found.
Gene-augmentation therapy with voretigene neparvovec (VN) appears to be safe and confers visual function benefits that persist up to 4 years in patients with biallelic RPE65 mutation-associated inherited retinal disease, as shown in an open-label phase III study.
Being inactive (zero 10-min bouts/week in moderate-to-vigorous physical activity [MVPA]) is associated with a higher risk of developing functional limitation in adults with knee osteoarthritis (OA), regardless of sedentary category, a study has found.
A recent systematic review and meta-analysis has revealed that about one in three adults with cerebral palsy are hypertensive, which stresses the importance of clinical screening for blood pressure (BP) in these individuals beginning in young adulthood.
Treatment with tocilizumab, an interleukin (IL)-6 receptor antagonist, is effective for corticosteroid sparing in patients with giant cell arteritis (GCA), suggests a study. However, tocilizumab allows for a prolonged remission in fewer than half of the patients following treatment discontinuation.
A pooled safety analysis of two phase III DISCOVER trials demonstrated the favourable safety profile of the novel interleukin(IL)-23p19-specific monoclonal antibody guselkumab through 1 year for psoriatic arthritis (PsA).
Monitoring estimated oxygen variation (EOV) using a wearable fitness tracker may facilitate early detection of coronavirus disease 2019 (COVID-19) symptom exacerbation and prevent untimely death, according to a new study.
Special Reports
The FreeStyle Libre™
flash glucose monitoring system includes a sensor which automatically measures
and continuously stores up to 8 ours of glucose readings, allowing patients to
monitor their glucose levels without the need for painful finger pricks.
Physicians play an important role in reviewing and analysing glucose data that
is available through LibreView to support patient management.
At the recent EMPIRE (Evidence on the Management Pathway In T2D with CVD Risk and REnal Impairment) Summit organised by Boehringer Ingelheim, several eminent speakers shared the latest updates on T2D management and the need for early treatment intensification to optimise patient outcomes.
At the recent Malaysian Myeloproliferative Neoplasms (MPN) Expert Forum, Professor Martin Griesshammer from the Johannes Wesling University Hospital in Germany highlighted the role of personalised clinical decision-making tools and treatment in early-stage myelofibrosis. Chaired by Dr Alan Teh, Consultant Haematologist at Subang Jaya Medical Centre, the virtual forum was organised by Novartis, in collaboration with the Malaysian Society of Haematology (MSH).
Technological advancements have improved glucose
monitoring and diabetes care, as well as empowered patients in self-care. The
introduction of continuous glucose monitoring systems (CGM), such as the
Abbott FreeStyle LibreTM, offers patients an alternative and
additional advantages to self-monitoring of blood glucose (SMBG).
DKD is the principal cause of ESRD and remains one of the most prevalent complications among patients with T2DM.Hyperglycaemia is the main factor in the development and progression of DKD; once established, it triggers multiple pathogenic processes (eg, hypertension, altered tubuloglomerular feedback, renal hypoxia, lipotoxicity, inflammation), leading to a progressive decline in GFR.
At the recent Malaysia Myeloproliferative Neoplasms (MPN) Expert Forum webinar, Associate Professor Dr Haifa Kathrin Al-Ali, Senior Consultant of Haematology and Oncology and the head of the Krukenberg Cancer Center, University Hospital of Halle (Saale), Germany, presented the case for earlier treatment of myelofibrosis (MF) and better symptom management. The webinar was organized by Novartis in collaboration with the Malaysian Society of Haematology (MSH), and chaired by Dr Chew Lee Ping, Consultant Haematologist from Hospital Umum Sarawak.
During the EMPIRE Summit sponsored by Boehringer Ingelheim, two distinguished speakers shared their insights into the evolving treatment landscape of DKD. Topics discussed include the role of SGLT-2iin fulfilling the unmet needs in DKD management and how evidence of their cardio renal-protective effects have altered clinical practice guidelines globally.
Conference Reports
Home-based inspiratory muscle training (IMT) – incorporated into COVID-19 rehabilitation programme – speeds up the recovery of patients in a UK study presented at ERS 2021.
Children with asthma are less likely to respond to inhaled corticosteroid (ICS) if they also happen to obese or overweight, suggests a study presented at ERS 2021.
Interim results of two phase III ORIENT trials presented at ESMO 2021 underscore the potential of a combination regimen comprising the PD-1 inhibitor sintilimab and chemotherapy (CT) as a first-line therapeutic alternative for gastrointestinal cancers, particularly advanced, recurrent, or metastatic oesophageal squamous cell carcinoma (SCC) and gastric/gastroesophageal junction (G/GEJ) adenocarcinoma.
Under 130 mm Hg – that’s how low clinicians can go in terms of systolic blood pressure (SBP) to reduce cardiovascular events in older, hypertensive Chinese patients, suggests the multicentre STEP* trial.
Infants born to mothers who were inactive during pregnancy were more likely to have low lung function compared with those whose mothers were active while pregnant, according to the PreventADALL study presented at ERS 2021.
The administration of inhaled budesonide for the treatment of early COVID-19 in adults reduced the probability of needing urgent medical care and time to recovery, according to findings from the STOIC* trial presented at ERS 2021.
Trastuzumab deruxtecan (T-Dxd) provides a highly clinically meaningful and statistically significant improvement in progression-free survival (PFS) vs trastuzumab emtansine (T-DM1) in second-line treatment of HER2-positive metastatic breast cancer (mBC), results of the phase III DESTINY-Breast03 trial have shown.
Multimedia
